Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15182047 | 0.91 | BRD4 (0.41) | MDM2MDM4TP53BACE1BRD4 | |
| SCHEMBL2641803 | 0.91 | BRD4 (0.41) | MDM2MDM4TP53BACE1BRD4 | |
| SCHEMBL15106634 | 0.91 | BRD4 (0.41) | MDM2MDM4TP53BACE1BRD4 | |
| SCHEMBL30869851 | 0.89 | MDM2 (0.36) | MDM2MDM4TP53BACE1BRD4 | |
| SCHEMBL18591886 | 0.87 | MDM2 (0.38) | MDM2MDM4TP53BACE1CASP3 | |
| SCHEMBL1692213 | 0.84 | CASP3 (0.39) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL18591846 | 0.84 | PTPN1 (0.39) | MDM2BACE1PTPN1 | |
| SCHEMBL30410248 | 0.83 | ALDH1A1 (0.42) | MDM4TP53CASP3 | |
| SCHEMBL25695323 | 0.83 | ALDH1A1 (0.42) | MDM4TP53CASP3 | |
| SCHEMBL23728631 | 0.81 | CASP3 (0.44) | MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | MDM2 165/4885MDM4 199/4885TP53 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.